Business Wire

“Look for the WELL Health-Safety Seal” Public Awareness Campaign Launches, Featuring Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th U.S. Surgeon General Richard Carmona

25.1.2021 16:00:00 EET | Business Wire | Press release

Share

As the world continues to battle COVID-19 and communities strive to get back to business, it is more important than ever to raise confidence in the safety of buildings and shared spaces. Today, Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th Surgeon General Richard Carmona came together in a new integrated ad campaign to raise awareness about the importance of the WELL Health-Safety Rating, an evidence-based third-party designation to verify that a building or space has taken the necessary steps to prioritize the health and safety of their staff, visitors and other stakeholders. The ambassadors encourage people to look for buildings and spaces with the WELL Health-Safety seal on their windows or doors to feel more confident in their decision to go inside.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005216/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

WELL Health-Safety Seal (Photo: Business Wire)

This national advertising campaign, a first from the International WELL Building Institute (IWBI), the global authority on how we can use our buildings and communities to advance the health and well-being of the people inside, explains the importance of health and safety through building design and operations as well as organizational policy, and sheds light on what the featured ambassadors have missed most during the pandemic. From Jennifer Lopez’s family movie nights to Robert DeNiro missing a “variety in existence,” each of these cultural influencers are feeling the longing for shared connection as much as the rest of us, even beyond the changes to their respective industries and day-to-day lives.

“This is more than an awareness campaign; it’s meant to ignite a movement. These ambassadors and cultural influencers are partnering with us because they truly believe in the mission – and how critical it is – to make buildings and shared spaces center on health going forward,” said Paul Scialla, Founder of the International WELL Building Institute and CEO of its parent company, Delos. “To succeed at scale means we are improving indoor spaces to help ensure that the people who visit them can be healthier and safer. This is a win for everyone involved.”

The WELL Health-Safety Rating brings together building expertise and nearly a decade of health science to promote indoor safety, creating an efficient and cost-effective opportunity to guide, validate, recognize and scale efforts to manage critical health and safety issues in shared spaces. The WELL Health-Safety Rating examines 22 features across five core areas – Cleaning and Sanitization Procedures, Emergency Preparedness Programs, Health Service Resources, Air and Water Quality Management, and Stakeholder Engagement and Communication – and requires a minimum of 15 criteria be met in order to achieve the rating and be awarded the WELL Health-Safety seal.

As such, the seal is a symbol of trust and confidence that is backed by science, structure and, most importantly, third-party verification. IWBI has seen thousands of buildings enroll in the program since its launch in July 2020, and expects significant global adoption to continue in 2021 and beyond.

“While the WELL Health-Safety Rating was a response to this moment in time, it was developed to address broader health and safety-related issues well into the future,” said Rachel Hodgdon, President and CEO of the International WELL Building Institute. “We collaborated with our global community to create something that’s flexible for all building types and organizational priorities. This consistency across market sectors means people will see the seal at their favorite restaurants, stadiums and hotels, and at their office, childcare center or college campus and know it stands for the same thing in every location, that science-based strategies have been implemented and safety has been prioritized.”

The WELL Health-Safety Rating was developed in response to market demand and informed by IWBI’s Task Force on COVID-19, which included nearly 600 public health experts, virologists, government officials, academics, business leaders, architects, designers, building scientists and real estate professionals. More than 1.5 billion square feet of space are enrolled in WELL offerings. To date, Yankee Stadium, the Empire State Building, JPMorgan Chase, RocketMortgage Field House, Amalie Arena, Spectrum Center, Simon Property Group, BB&T Center, Aimbridge Hospitality and AT&T Stadium, among others, have achieved the WELL Health-Safety Rating.

The public awareness campaign launched today and comes to life through TV, digital video and social advertising. TV commercials will appear nationally through early spring 2021. The campaign creative was developed by advertising agency SWAT by Kirshenbaum, directed by Spike Lee and produced by Pony Show Entertainment.

“From an enterprise standpoint, this is an exceptionally exciting time for all of us,” said Delos CMO Anthony Antolino. “Helping everyone to get back to business with confidence is critical, and these celebrity ambassadors are key in helping spread the word.”

For more information about the campaign, please visit www.WellHealthSafety.com.

About the International WELL Building Institute
The International WELL Building Institute (IWBI) is a public benefit corporation and the world’s leading organization focused on deploying people first places to advance a global culture of health. The WELL Building Standard anchors a WELL ecosystem that includes WELL v2, the WELL Community Standard, the WELL Health-Safety Rating and WELL Accredited Professionals. IWBI mobilizes its community through the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and well-being for everyone, everywhere. More information on WELL can be found here.

International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Workforce, WELL Health-Safety Rating, WE ARE WELL, WELL and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Samantha Wolf
Tel. 646-935-4032
samantha.wolf@ketchum.com

Jamie Matos
media@wellcertified.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye